Anpac Bio-Medical Presenting ‘Breakthrough’ Cancer Screening Tech/Research At Breast Cancer Symposium

SACRAMENTO, Calif., Sept. 16, 2015 — Anpac Bio-Medical Science Company Chief Executive Officer Dr. Chris Yu and Anpac scientists will be presenting “breakthrough,” Breast Cancer screening and early detection research results at the upcoming “Breast Cancer Symposium” in San Francisco, California, September 25-27, 2015.

Reporting outcomes generated through Anpac’s novel, non-invasive, “Cancer Differentiation Analysis” (CDA) technology, Anpac’s team will share with Symposium attendees Anpac’s consistent Breast Cancer detection sensitivity and specificity rates of over 80% to date (versus standard/traditional early detection tests, generating an approximately 30% sensitivity/specificity rate).

Published earlier this year as “game changing”, by the Nobel Prize Laureate Summit on Biomedical Science (NPLS), research indicates Anpac’s CDA medical devices effectively reinvent early Breast Cancer screening and detection. By analyzing simple, in vitro, whole, “Blood Biopsies”, and applying Anpac’s proprietary, multi-level, multi-parameter, diagnostic algorithms, Anpac’s CDA technology identifies Breast Cancer with measurably-greater sensitivity, specificity, and accuracy, than most current, conventional Breast Cancer early screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing (such as imaging).

Of most importance to Symposium participants, Anpac’s CDA technology can reveal threatening Breast Cancer cells, before they form into tumors – key to patient survival rates. According to Cancer Research U.K., more than 90% of women diagnosed with breast cancer at the earliest stage survive their disease for at least five years; compared to around 15% for women diagnosed with the most advanced stage of disease (http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/breast-cancer/survival#heading-Three).

The scientific Abstract outlining Anpac’s CDA Breast Cancer research samples/method, results, etc., will post September 25.

“We are excited to share our CDA findings at the Breast Cancer Symposium,” states Dr. Yu. “Our study results are very encouraging. And we hope by sharing them that we can form alliances with other Breast Cancer advocacy organizations, to expedite and launch CDA Breast Cancer clinical trials early next year. Working quickly and in partnership, we can save millions of lives through Anpac CDA screening.”

The Breast Cancer Symposium, co-sponsored by the American Societies of Breast Cancer Surgeons, Clinical Oncology, Radiation Oncology, and Surgical Oncology, is an educational, collaborative forum highlighting clinically relevant, translational science, affecting current breast cancer management.

Related Links

©2019 Anpac Bio-Medical Science Co., Ltd.
;